[3-[[5-(Hydroxymethyl)-2-methylsulfanylpyrimidin-4-yl]amino]phenyl]carbamic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3-[[5-(Hydroxymethyl)-2-methylsulfanylpyrimidin-4-yl]amino]phenyl]carbamic acid
• 英文别名: [3-[[5-(hydroxymethyl)-2-methylsulfanylpyrimidin-4-yl]amino]phenyl]carbamic acid
• 化学式: C₁₃H₁₄N₄O₃S
• 分子量: 306.34
• InChiKey: PUWLOVFXXMCWBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE FUSIONNÉS, COMPOSITIONS ET APPLICATIONS MÉDICALES ASSOCIÉES
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2021062327A1

  公开（公告）日：2021-04-01

  The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

  本公开涉及一类式I的融合嘧啶化合物，它们的立体异构体、互变异构体、药用可接受盐、多型体、溶剂合物和水合物。本公开还涉及制备这些融合嘧啶化合物的方法，以及含有它们的药物组合物。
• Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use
  申请人：AMGEN INC.

  公开号：US20140249131A1

  公开（公告）日：2014-09-04

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

  这项发明涵盖了化合物、类似物、前药和其药用盐，以及用于预防和治疗癌症的药物组合物、用途和方法。
• Inhibitors of EGFR and/or HER2 and methods of use
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US11186574B2

  公开（公告）日：2021-11-30

  The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

  本申请涉及一种具有式 X 的化合物：该化合物可调节 HER2 和/或其突变体和/或表皮生长因子受体和/或其突变体的活性；一种包含该化合物的药物组合物；以及一种治疗或预防 HER2 和/或其突变体和/或表皮生长因子受体和/或其突变体在其中起作用的疾病的方法。
• SUBSTITUTED 7-OXO-PYRIDO [2, 3-D]PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP2961750A1

  公开（公告）日：2016-01-06
• INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE
  申请人：HATCHER John M.

  公开号：US20200199121A1

  公开（公告）日：2020-06-25

  The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.